Statins: real benefits, muscle pain and the myths

In short

Statins are among the most thoroughly studied drugs in medical history and consistently reduce the risk of heart attacks and strokes in people with elevated cardiovascular risk.
The difference between relative and absolute risk matters: a 30 percent relative risk reduction means something very different for someone whose baseline risk is 1 percent versus 20 percent.
Mild muscle aching is relatively common, but true statin-related myopathy is rare. Much of what is attributed to statins may have other explanations.
Stopping a statin out of fear of imagined muscle symptoms leaves a person facing a real cardiovascular risk, and this trade-off deserves an honest conversation with your doctor.
LDL, liver enzymes, and creatine kinase are monitored regularly during treatment to confirm the drug is working and causing no harm.

What this article covers

What are statins and how do they work?
Relative versus absolute risk: the difference that matters to you
Muscle pain: the truth behind the most common reason for stopping
Statins and the liver: genuine concern or exaggerated fear?
Statins and diabetes risk: what the evidence says
Who genuinely needs a statin and who may not?
Monitoring during statin treatment
Addressing the common myths about statins

What are statins and how do they work?

Statins inhibit an enzyme called HMG-CoA reductase, which controls the main step in the liver's cholesterol production. When this enzyme is slowed down, liver cells make less cholesterol and compensate by pulling LDL (low-density lipoprotein, the harmful cholesterol) from the bloodstream through receptors on the cell surface. The result is a measurable and sustained fall in LDL levels.

The most widely used statins are atorvastatin, rosuvastatin, and simvastatin. They differ in their potency at reducing LDL and in their likelihood of certain interactions. The choice of drug and dose depends on your total cardiovascular risk and your tolerance of the drug.

The benefit of statins extends beyond LDL lowering. They have additional effects known as pleiotropic effects: they reduce inflammation in blood vessel walls and stabilise the cholesterol plaques that can rupture and cause a heart attack. This is why statins are given even to people whose LDL is not dramatically elevated but who have already had a heart attack.

Relative versus absolute risk: the difference that matters to you

When you read that a statin reduces the risk of a heart attack by 30 percent, this sounds impressive. But this is a relative risk reduction (RRR), and understanding it without knowing your baseline risk can be misleading. A systematic review published in 2022 in JAMA Internal Medicine found that many patients are not clearly informed about this distinction, and that it affects their decisions about treatment.

Absolute risk reduction (ARR) is what matters for you personally. If your baseline risk of a heart attack in the next 10 years is 1 percent, then a 30 percent relative reduction means it becomes 0.7 percent, a difference of 0.3 percentage points in absolute terms. If your baseline risk is 20 percent, the same relative reduction means it falls to 14 percent, a difference of 6 percentage points. Both are genuine reductions, but the real-world impact is very different.

This does not mean statins are unhelpful at lower risk levels, but it means the right medical decision must be based on calculating your actual risk rather than on a percentage figure alone. This is why doctors use standardised tables and calculators to estimate your cardiovascular risk before deciding whether to start treatment.

Relative versus absolute risk: what the numbers mean

Baseline 10-year risk	30% relative reduction	Risk after drug	Absolute difference
1%	30%	0.7%	0.3%
10%	30%	7%	3%
20%	30%	14%	6%

Muscle pain: the truth behind the most common reason for stopping

Muscle aching or heaviness after starting a statin is the most frequently reported complaint. The European Atherosclerosis Society Consensus Panel estimated that between 5 and 10 percent of patients experience muscle-related symptoms on statins. However, true statin myopathy with a significant rise in the muscle enzyme CK (creatine kinase) is less common, and the serious condition called rhabdomyolysis, in which muscle fibres break down, is very rare.

What complicates the picture is the nocebo effect: when a person reads that statins cause muscle pain before starting the drug, they become more sensitive to ordinary everyday muscle soreness and attribute it to the medicine. Controlled trials that compared statins to a placebo found that the rate of muscle complaints was similar in both groups when patients did not know which tablet they were taking.

If muscle pain appears after starting a statin, see your doctor to check CK levels. Mild pain with a normal CK is usually managed by adjusting the dose or switching to a different statin. Severe pain with a substantially elevated CK warrants stopping the drug and reviewing the treatment plan. Do not stop on your own, because stopping unilaterally leaves you exposed to a cardiovascular risk that is real and measurable.

Statins and the liver: genuine concern or exaggerated fear?

The widespread belief that statins damage the liver is not well supported by the evidence. A mild transient rise in liver enzymes occurs in a small proportion of users, but it typically resolves on its own even if the drug is continued without any change. True clinically significant liver injury attributable to statins alone is very uncommon in large observational studies, and the absolute number of serious events is far smaller than many patients fear based on what they read online or hear from others.

Your doctor checks liver enzymes before starting the drug and after a short period. If they rise substantially, the dose may be adjusted or the statin changed. People with active liver disease may not be suitable candidates, but this is quite different from non-alcoholic fatty liver disease (NAFLD), which is very common in the region and is not in itself a contraindication.

NAFLD is extremely prevalent across the Arab world, driven by high rates of obesity and type 2 diabetes. Most evidence suggests that statins are safe in NAFLD and some studies indicate potential benefit. The decision depends on the degree of liver inflammation and whether cirrhosis has developed, not on the mere presence of a fatty liver.

Statins and diabetes risk: what the evidence says

Long-term statin use modestly increases the probability of developing type 2 diabetes in people who are already predisposed to it. This finding comes from pooled analyses of large randomised trials and is statistically robust, so it should not be dismissed. But context is essential for understanding its weight.

People taking a statin are usually doing so because their cardiovascular risk is elevated. The prevention of a heart attack or a stroke by the statin substantially outweighs the modest increase in diabetes risk, particularly in someone who was already at risk of diabetes regardless. If diabetes appears it can be treated, whereas a major heart attack does not always give a second chance.

If you are at risk of diabetes and taking a statin, this is an additional reason to monitor your blood sugar, maintain a healthy weight, and follow a reasonable diet, not a reason to stop the drug without consulting your doctor.

Who genuinely needs a statin and who may not?

The consensus guidelines on lipid management in the Middle East, updated in 2021 by a regional panel of experts, classify patients by their total cardiovascular risk. People who have already had a heart attack, stroke, or established coronary artery disease are at very high risk and need a statin at a sufficient dose to reach a specific LDL target. People with multiple risk factors such as diabetes, hypertension, and smoking are also classified as high risk.

By contrast, a young healthy person with a mildly elevated LDL and otherwise normal risk factors may not have a total cardiovascular risk high enough to justify drug treatment, and lifestyle change with close monitoring may be sufficient. The decision is never about the LDL number alone but about the full clinical picture.

A 2016 study in the International Journal of Cardiology documented that non-adherence to statins leaves a measurable gap in cardiovascular protection and that this residual risk is real. If you are hesitant about continuing, an honest conversation with your doctor about your specific risk and the expected benefit is far more productive than stopping silently.

Monitoring during statin treatment

After starting a statin or changing the dose, LDL is checked after six to eight weeks to confirm that the target has been reached. If not, an additional agent such as ezetimibe, which reduces cholesterol absorption from the gut, may be added. The LDL target varies with your risk level and may be below 70 or even 55 milligrams per decilitre in very high-risk patients.

Liver enzymes are checked before starting and as needed afterwards. Creatine kinase is not checked routinely when there are no muscle symptoms, but it is ordered when a patient complains of muscle pain. Modern guidelines have moved away from very frequent routine liver enzyme monitoring because clinically significant elevations are rare.

Many patients stop their statin in summer, during Ramadan, or after hearing a worrying story from a friend, and every unplanned interruption leaves them with a temporarily higher LDL and elevated risk. If you have doubts about continuing, raise them with your doctor directly rather than stopping on your own initiative.

Monitoring statin treatment

Before starting Check LDL, liver enzymes, and set the LDL target
After 6-8 weeks Recheck LDL to confirm the target is reached
If muscle pain Check CK and assess symptoms with your doctor
Annually Review overall risk and confirm continuation

Addressing the common myths about statins

One of the most persistent myths is that statins are promoted by doctors without genuine need. In reality, statins are among the most extensively studied drugs in clinical medicine. Dozens of large randomised controlled trials involving hundreds of thousands of people have demonstrated their effect on reducing cardiac events in people at elevated risk. Collective scepticism about this body of evidence is not supported by any counter-evidence of comparable quality or scale, and the people who stop a proven drug based on unverified online claims take a real risk.

Another myth is that dietary cholesterol is the only problem and that avoiding eggs is sufficient. The truth is that the liver manufactures most of the body's cholesterol from other dietary inputs, particularly saturated fats in fatty meat and full-fat dairy, and trans fats in processed fried foods. Dietary cholesterol has a smaller effect on blood LDL than was once thought. Statins target the liver's cholesterol factory directly, which is why they are so much more effective than diet alone in people with genetically driven high LDL or established cardiovascular disease.

A third myth is that once started, a statin can never be stopped. The drug is prescribed because cardiovascular risk is ongoing, and if circumstances genuinely change, the doctor can reassess. However, for someone prescribed it after a heart attack or stroke, continuing indefinitely is the evidence-based recommendation, and stopping it prematurely carries a well-documented increase in the risk of a further event. If you feel well and your cholesterol appears controlled, it is tempting to stop but this is exactly the wrong conclusion: the drug is working, and stopping removes the protection.

In the Sihtak app you can store your lipid test results including LDL, HDL, and total cholesterol, set daily reminders for your statin dose, and ask the AI assistant to explain what your cholesterol numbers mean or how much benefit to expect from your drug at your risk level. Your doctor remains the person who adjusts your treatment, but being informed makes every consultation more productive.

Frequently asked questions

Is a statin a lifelong drug?

For someone who has already had a heart attack, stroke, or established coronary disease, a statin is typically lifelong because the cardiovascular risk is ongoing. For someone taking it purely for prevention, the decision may be reviewed over time. Do not stop without discussing it with your doctor.

Does statin interact with food?

Simvastatin is significantly affected by grapefruit juice, which raises drug levels in the blood and increases the risk of muscle side effects. Atorvastatin and rosuvastatin are less affected. Fatty meals do not break down the drug but undermine the overall goal of the treatment.

Can I take my statin in the morning instead of at night?

Simvastatin is taken at night because the liver makes most of its cholesterol during sleep. Atorvastatin and rosuvastatin have longer half-lives and can be taken at any time of day consistently. Follow the timing your doctor specifies.

Do statins cause memory loss?

Reports of memory problems with statins exist but the evidence is weak and inconsistent. Large studies do not confirm this association, and some evidence suggests that protecting the heart may also protect the brain over the long term. If you notice memory changes, tell your doctor so other causes can be considered.

Can I replace a statin with cholesterol-lowering foods?

Foods such as oats, nuts, and healthy oils help improve lipids but their effect on LDL is considerably smaller than a statin. For people with a high cardiovascular risk or very elevated LDL, diet alone is rarely sufficient to reach the target.

Is a high cholesterol always a cause for concern?

An elevated LDL alone is not the final verdict. Your doctor assesses total cardiovascular risk, which includes age, sex, blood pressure, diabetes, smoking history, and family history. Some people live with elevated LDL without a problem, while others with a lower LDL need treatment because of their other risk factors.

Can I stop the statin during Ramadan?

There is no medical reason to stop a statin during Ramadan. Statins do not require food to work and are not affected by fasting. The dose timing may be adjusted to fit the eating schedule of Ramadan, but the drug should be continued. Stopping for a month and restarting is not recommended.

Sources

This content is for health education only and is not a substitute for medical advice. If you have symptoms that worry you, see your doctor.